Rational Use of Recombinant Factor VIIa in Clinical Practice
نویسندگان
چکیده
منابع مشابه
Use of Recombinant factor VIIa in Obstetrics
6 The objective of this review article was to evaluate the current literature on the increasing off-label use of rFVIIa in the management of critical obstetric hemorrhage. Given the lack of high-level evidence, there is a need to review the clinical indications, observed response and adverse events. This review is designed to aid practitioners in deciding when and how to administer rFVIIa; It m...
متن کاملRecombinant factor VIIa. An update on its clinical use.
Recombinant activated factor VII (rFVIIa, NovoSeven) has been successfully used to treat bleeding episodes in patients with antibodies against coagulation factors VIII and IX. In recent years, rFVIIa has also been employed for the management of uncontrolled bleeding in a number of congenital and acquired haemostatic abnormalities. Based on a literature search, this review examines the current k...
متن کاملRecombinant factor VIIa: a review on its clinical use.
Recombinant activated factor VII (rFVIIa) (NovoSeven) is a novel hemostatic agent originally developed to treat bleeding episodes in hemophilic patients with inhibitors against coagulation factors VIII and IX. In recent years, rFVIIa has also been employed for the management of uncontrolled bleeding in a number of congenital and acquired hemostatic abnormalities. Based on a literature search in...
متن کاملThe Use of Recombinant Factor VIIa*
As described in detail in other chapters of this volume, conditions with excessive bleeding, as are seen with uterine rupture, placenta accreta, abruption and uterine atony, often require intensive resuscitation with blood components and coagulation factors. In such circumstances, blood transfusion may be life-saving, but on occasion involves exposing the patient to additional risks. Over the y...
متن کاملOff-label use of recombinant factor VIIa in pediatric patients.
OBJECTIVE To examine off-label recombinant factor VIIa (rFVIIa) use in pediatric patients including clinical indications, dose, adverse events, and outcomes. METHODS All pediatric patients entered into the Haemostasis Registry from 75 participating hospitals were analyzed. RESULTS Three hundred and eighty-eight pediatric patients received off-label rFVIIa from 2003 to 2009. Median age was 1...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Hematology and Blood Transfusion
سال: 2013
ISSN: 0971-4502,0974-0449
DOI: 10.1007/s12288-013-0240-9